Related Experiment Video
Updated: Apr 28, 2026
Heterotopic Mucosal Engrafting Procedure for Direct Drug Delivery to the Brain in Mice
Published on: July 16, 2014
Intranasal epidermal growth factor treatment rescues neonatal brain injury
Joseph Scafidi1, Timothy R Hammond2, Susanna Scafidi3
11] Center for Neuroscience Research, Children's National Medical Center, Washington DC 20010, USA [2] Department of Neurology, Children's National Medical Center, Washington DC 20010, USA.
Insights
Targeting epidermal growth factor receptor (EGFR) signaling in oligodendrocyte progenitor cells promotes brain repair and functional recovery in a mouse model of preterm brain injury. This approach offers a potential treatment for white matter injury in premature infants.
Area of Science:
- Neuroscience
- Developmental Biology
- Regenerative Medicine
Background:
- Neonatal brain injury in very preterm infants (less than 32 weeks' gestation) leads to chronic neurodevelopmental impairments, with diffuse white matter injury (DWMI) being a common cause.
- Failure of oligodendrocyte progenitor cell maturation is a key factor contributing to DWMI.
- Epidermal growth factor receptor (EGFR) signaling plays a crucial role in oligodendrocyte development.
Purpose of the Study:
- To investigate whether enhancing EGFR signaling can stimulate endogenous progenitor cells after brain injury.
- To determine if EGFR activation promotes cellular and behavioral recovery in the developing brain.
- To assess the clinical feasibility of targeting EGFR for treating white matter injury in premature infants.
Main Methods:
- Utilized a mouse model of very preterm brain injury.
- Administered interventions including selective human EGFR overexpression in oligodendrocyte lineage cells and intranasal heparin-binding EGF.
- Inhibited EGFR signaling using a targeted cancer therapy agent to confirm its role in recovery.
Main Results:
- Enhanced EGFR signaling decreased oligodendroglia death and increased the generation of new oligodendrocytes from progenitor cells.
- Interventions promoted functional recovery, diminished ultrastructural abnormalities, and alleviated behavioral deficits in white-matter-specific tests.
- EGFR activation was confirmed as critical for oligodendrocyte regeneration and functional recovery following DWMI.
Conclusions:
- Targeting EGFR in oligodendrocyte progenitor cells after injury is a clinically feasible strategy.
- This approach shows potential for treating white matter injury and improving outcomes in premature infants.
- The study provides direct evidence for EGFR's role in brain repair mechanisms following neonatal injury.
Abstract:
There are no clinically relevant treatments available that improve function in the growing population of very preterm infants (less than 32 weeks' gestation) with neonatal brain injury. Diffuse white matter injury (DWMI) is a common finding in these children and results in chronic neurodevelopmental impairments. As shown recently, failure in oligodendrocyte progenitor cell maturation contributes to DWMI. We demonstrated previously that the epidermal growth factor receptor (EGFR) has an important role in oligodendrocyte development. Here we examine whether enhanced EGFR signalling stimulates the endogenous response of EGFR-expressing progenitor cells during a critical period after brain injury, and promotes cellular and behavioural recovery in the developing brain. Using an established mouse model of very preterm brain injury, we demonstrate that selective overexpression of human EGFR in oligodendrocyte lineage cells or the administration of intranasal heparin-binding EGF immediately after injury decreases oligodendroglia death, enhances generation of new oligodendrocytes from progenitor cells and promotes functional recovery. Furthermore, these interventions diminish ultrastructural abnormalities and alleviate behavioural deficits on white-matter-specific paradigms. Inhibition of EGFR signalling with a molecularly targeted agent used for cancer therapy demonstrates that EGFR activation is an important contributor to oligodendrocyte regeneration and functional recovery after DWMI. Thus, our study provides direct evidence that targeting EGFR in oligodendrocyte progenitor cells at a specific time after injury is clinically feasible and potentially applicable to the treatment of premature children with white matter injury.
